Cepheid Mpox Test Gets Emergency Use Listing by WHO
WHO has granted Cepheid’s Xpert Mpox test Emergency Use Listing, enabling rapid, point-of-care mpox detection to support outbreak management.
Tag: Cepheid
All
Latest
All
Latest
FDA Issues First Emergency Use Authorization for Point-of-Care Covid-19 Diagnostic
The agency’s EUA grants permission for Cepheid’s test to be used in high- and moderate-complexity CLIA-certified laboratories as well as in certain patient care settings.
All
Latest
September 2016 Tech Guide: Molecular Diagnostic Instruments
This month’s issue features molecular diagnostic instruments from such companies as Cepheid, Hologic, and Qiagen.
Molecular Diagnostics System Extends Reach
Under a nonexclusive agreement, Henry Schein will market Cepheid’s GeneXpert system to its non-acute care laboratory customers in the United States.
Read MoreUSAID, Cepheid Join Forces to Battle Multidrug-Resistant Tuberculosis
Cepheid has signed a memorandum of understanding representing its intention to work with USAID to support the White House’s national action plan for combating MDR-TB.
Read More
FDA Clears On-Demand Trichomoniasis Test
Cepheid’s qualitative in vitro diagnostic identifies trichomoniasis in symptomatic and asymptomatic female patients, using urine, endocervical swab, or vaginal swabs collected by the patient in a clinical setting.
Read More